公开(公告)号：US20220169696A1

公开(公告)日：2022-06-02

申请号：US17436934

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: C07K14/725 ,  C12N9/22 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  A61K35/17 ,  C07K14/74

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220168346A1

公开(公告)日：2022-06-02

申请号：US17436939

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: A61K35/17 ,  A61P35/00 ,  A61P37/04 ,  C07K14/725 ,  C07K14/74 ,  C12N15/62 ,  C12N15/86 ,  C12N5/0783

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220281942A1

公开(公告)日：2022-09-08

申请号：US17631825

申请日：2020-07-29

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji SUGATA ,  Kayoko SASO

IPC: C07K14/725 ,  A61P35/04 ,  C07K16/30 ,  C07K14/55 ,  C07K14/54

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220168347A1

公开(公告)日：2022-06-02

申请号：US17436943

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C12N15/62

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220324938A1

公开(公告)日：2022-10-13

申请号：US17598763

申请日：2020-03-24

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: C07K14/725 ,  C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a tyrosinase epitope, a MAGA-A1 epitope, a MART1 epitope, a MAGE-A3 epitope, or an SSX2 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220152105A1

公开(公告)日：2022-05-19

申请号：US17436936

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: A61K35/17 ,  C07K14/725 ,  A61K38/20 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/375 ,  A61K31/436 ,  C07K14/74 ,  A61K39/00 ,  A61P35/00 ,  C12N15/113 ,  C12N9/22 ,  C12N15/86

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220169695A1

公开(公告)日：2022-06-02

申请号：US17436929

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: C07K14/725 ,  C12N15/113 ,  C12N9/22 ,  C07K16/28 ,  A61K35/17 ,  C07K14/74 ,  C12N5/0783 ,  A61K39/00

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220152104A1

公开(公告)日：2022-05-19

申请号：US17436931

申请日：2020-03-03

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji MURATA ,  Kayoko SASO

IPC: A61K35/17 ,  C07K14/725 ,  A61K45/06 ,  A61P35/02 ,  A61P35/04 ,  C07K14/74 ,  C07K14/71 ,  C12N15/113

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220275047A1

公开(公告)日：2022-09-01

申请号：US17631831

申请日：2020-07-29

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji SUGATA ,  Kayoko SASO

IPC: C07K14/725 ,  C12N15/113 ,  C07K16/28 ,  A61K35/17 ,  C07K14/74

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：US20220275046A1

公开(公告)日：2022-09-01

申请号：US17631830

申请日：2020-07-29

Applicant: University Health Network

Inventor： Naoto HIRANO ,  Kenji SUGATA ,  Kayoko SASO

IPC: C07K14/725 ,  A61P35/04 ,  C07K16/30 ,  C07K14/54

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MAGE-A2 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.